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AbstrAct
Objectives Segmented filamentous bacteria (SFB) 
have been detected in a wide range of different animal. 
Recently, the presence of SFB-like bacteria was shown 
in biopsies of the terminal ileum and ileocecal valve of 
both patients with ulcerative colitis and control subjects. 
The aim of this study was to verify whether PCR methods 
could be used for the detection of SFB in biopsy of 
patients with ulcerative colitis and its relationships with 
the disease stage.
Methods PCR methods were used to identify SFB in 
biopsies from the terminal ileum of patients with ulcerative 
colitis, showing that this approach represents a useful 
tool for the detection of SFB presence and analysis of the 
bacterial load.
results Our analysis detected SFB in all faecal samples 
of children at the time of weaning, and also show that 
putative SFB sequences are present in both patients with 
ulcerative colitis and control subjects. Results obtained 
using real-time quantitative PCR analysis confirm the 
presence of putative SFB sequences in samples from the 
terminal ileum of patients with ulcerative colitis and in 
control subjects.
conclusions The presence of putative SFB sequence in 
both patients with ulcerative colitis and control subject 
suggests that SFB cannot be considered as being uniquely 
associated with the disease. The second conclusion is that 
among the patients with ulcerative colitis, a tendency does 
exist for active disease samples to show higher SFB load, 
opening new perspectives about possible identification 
and pharmacological manipulation of SFB-mediated 
processes for new therapeutic strategy.
IntroductIon
Segmented filamentous bacteria (SFB) 
are Gram-positive bacteria which cannot 
be cultured with methods available in clin-
ical settings. SFB were discovered in 1849 
by Joseph Leidy in the intestines of myria-
pods and termites and reported as ‘jointed 
threads’; due to their peculiar shape, Leidy 
called these bacteria Arthromitus,1 but they 
are generally simply referred to SFB, a 
distinct lineage of the Clostridiaceae still 
pending with respect to precise systematic 
identification. Subsequently, SFB have 
been detected in a wide range of different 
animals including insects, fishes, birds and 
mammals.2 3 Recently, the interest on SFB 
has been renewed by two important studies 
showing that the SFB presence represents a 
required condition for a specific and coordi-
nated induction of T-cell activity, in particular 
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summary box
What is already known about this subject?
 ► The detection of segmented filamentous bacteria 
(SFB) presence and load is of pivotal relevance 
to evaluate its role in the pathogenesis of 
inflammatory and autoimmune human pathologies.
 ► SFB is virtually present in terminal ileum of all the 
animals, including mouse, rat, chicken and fish.
 ► The presence of SFB in human biopsies has been 
demonstrated on the basis of a single observation 
based on optical microscopy.
 ► In human, PCR-based SFB sequences have been 
detected in faecal samples but its presence in 
human colon diseases is still unclear.
 ► PCR-based SFB detection has been developed but 
not applied to human biopsies.
What are the new findings?
 ► PCR-based SFB sequences have been quantified in 
human biopsies from terminal ileum.
 ► SFB sequences are present in both patients with 
colorectal ulcerative colitis (RCU) and control 
subjects.
 ► SFB cannot be considered as being uniquely 
associated with the RCU pathology.
 ► A possible tendency to be further confirmed on a 
higher number of patients does exist between SFB 
load and the activity of RCU disease.
How might it impact on clinical practice in the 
foreseeable future?
 ► The impact of this study in the clinical practice is 
related to possible diagnosis, therapeutic treatment 
and patient stratification of ulcerative colitis during 
acute phase and remission. 
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with respect to T helper 17 (Th-17) lineage and regula-
tory T-cell responses.4 5 As a result of this novel informa-
tion, the fascinating hypothesis that these bacteria may 
play a role in the pathogenesis of autoimmune diseases 
has been proposed and then confirmed in animal models 
of multiple sclerosis, autoimmune arthritis and autoim-
mune diabetes.6–8 
The presence of SFB in humans has been described 
following single observation based on optical micros-
copy.7 However, clear morphological data remain still 
scarce in humans.9 10 We have recently shown the pres-
ence of SFB-like bacteria in biopsies of the terminal 
ileum and ileocecal valve of patients with ulcerative colitis 
and control subjects.11 On the other hand, we and other 
authors have published several ultrastructural studies 
demonstrating the presence of SFB in animal models. In 
mice, rats, chickens and fish, a holdfast segment of SFB is 
anchored to enterocytes of the specialised epithelium of 
the Peyer’s patches.12–16 In animal models, SFB appears 
at the time of weaning, and then expands to become one 
of the dominant bacteria. Later on, SFB load decreases 
becoming stable in adult animals probably in relation to 
age-dependent maturation and activity of the immune 
system.17 It is difficult to validate similar data in humans, 
with follow-up studies of children from weaning to adult 
age. However, Yin et al analysed fresh faecal samples18 
and showed that SFB colonisation is age dependent 
in humans with the majority of individuals colonised 
within the first 2 years of life, and also that this coloni-
sation disappeared by the age of 3 years. Observations in 
animal models suggest in any case that SFB are involved 
in driving the maturation and the differentiation of 
component of the gut-associated lymphoid tissue in all 
the animal models.19 20
Since SFB requires very complex in vitro growth condi-
tions,21 this bacterium remains non-culturable with 
commonly available methods. Recently, SFB genome 
sequences of rat, mouse and rainbow trout have been 
published and primers for PCR-based molecular analyses 
designed by alignment of published 16S rRNA sequences 
from SFB from mouse, rat and chicken.22–25 Since existing 
data of the presence and prevalence of SFB in humans 
are still weak, it is evident that detection of SFB presence 
and load is of pivotal relevance to evaluating its role in the 
pathogenesis of inflammatory and autoimmune human 
pathologies. Considering that the availability of reliable 
diagnostic methods is a crucial point, we tested and 
compared primers used in previous PCR studies. The aim 
of this part of the study was to evaluate whether the use 
of these putative SFB-specific primers allows performing 
both qualitative and quantitative PCR (qPCR) analyses in 
biopsies from the terminal ileum of patients with ulcer-
ative colitis and in subjects without evidence of intestinal 
disease. To our knowledge, this is the first time in which 
PCR is performed to identify SFB in biopsies from the 
terminal ileum instead of in faecal samples. The reason 
for this choice is related to the importance of studying 
SFB directly in their colonisation site, where they perform 
the relative biological activities, that is, in the specialised 
epithelium and M cells of the Peyer's patches. Of course, 
the identification of SFB in patient’s stools by any avail-
able technique remains of pivotal importance from a 
diagnostic point of view (when the pathogenic role of this 
agent will be clarified). However, it also appears of great 
interest to show whether the bacteria are present in the 
areas in which they complete their life cycle and possibly 
play their pathogenic role. In this preliminary open pilot 
study, we evaluated the presence and density of SFB in 
bioptic samples of terminal ileum and ileocecal valve of 
patients with ulcerative colitis and control subjects by 
using PCR quantitative and qualitative methods.
Methods
Patients and control subjects
For the purposes of this pilot open study, 10 patients 
in follow-up for ulcerative colitis previously diagnosed 
(six males and four females, age 28–70 years) and eight 
subjects without endoscopic evidence of intestinal disease 
(four males and four females, age 36–72 years) referred 
to the Digestive Endoscopy Service of the Hospital of 
Ferrara and the Sacco Hospital of Milan were recruited 
prior informed and written consent. According to the 
protocol approved by the local ethics committee, two 
biopsies from the terminal ileum and one biopsy from 
the ileocecal valve have been taken in each subject: one 
of the biopsies taken from the terminal ileum was in 
formalin-buffered solution for the routine histopatho-
logic examination, the other two biopsies, one from the 
terminal ileum and the other one from the ileocecal valve, 
were immediately frozen at −80°C in suitable cryovials 
which were then transferred into free nitrogen within 
a few hours for PCR analysis. Patients with severe ulcer-
ative colitis or relevant clinical conditions, for example, 
toxic megacolon, tumours, severe liver or kidney failure, 
and patients who had recently (<3 months) received or 
who were under treatment with antibiotics or cortico-
steroids, immunosuppressants or biological agents were 
also excluded from the study because of the possible 
influence on SFB presence and density. A control group 
of healthy subjects, matched for age and sex, recruited 
among subjects performing colonoscopy for colorectal 
cancer screening were also recruited, provided they had 
not taken antibiotics in the previous 3 months and ileoco-
lonoscopy was negative regarding mucosal lesions.
dnA extraction from stool
DNA extraction from frozen stool was performed 
using Stool DNA Extraction Mini Kit (Fisher Molecular 
Biology, Trevose, Pennsylvania, USA) according to the 
manufacturer’s instruction. Briefly, 100 mg of frozen 
stool was lysed with glass beads, proteinase K and lysis 
buffer; vortexed; and incubated for 10 min at 70°C. To 
ensure lysis of Gram-positive bacteria, samples were incu-
bated at 95°C for 5 min under vigorous shaking. Inhib-
itors and contaminants were removed by buffer system 
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Table 1 Employed primers
Name Sequence Tm (°C) Length (nt)
SFB F*† 5′-AGG AGG AGT CTG CGG CAC ATT AGC-3′ 62.9 24
SFB R*† 5′-TCC CCA CTG CTG CCT CCC GTA G-3′ 65.4 22
BAC 1114 F‡† 5′-CGG CAA CGA GCG CAA CCC-3′ 63.0 18
BAC 1275 R‡† 5′-CCA TTG TAG CAC GTG TGT AGC C-3′ 58.3 22
IL-8 prom F§¶ 5′-TCA CCA AAT TGT GGA GCT TCA GTA T-3′ 66.4 25
IL-8 prom R§¶ 5′-GGC TCT TGT CCT AGA AGC TTG TGT-3′ 65.8 24
*Sequences for SFB amplification are taken from Suzuki et al26 and Shukla et al27
†Primers were purchased from IDT (IDT Integrated DNA Technologies, Coralville, Iowa, USA).
‡Sequences for total bacteria amplification are taken from Denman and McSweeney28 and Yin et al18
§Sequences for IL-8 genomic DNA amplification are taken from Finotti et al29
¶Primers were purchased from Sigma-Aldrich (Sigma-Aldrich, St.Louis, Missouri, USA).
IL-8, interleukin-8; SFB, segmented filamentous  bacteria. 
and DNA-binding column. Purified DNAs were eluted 
with 50 µL of preheated elution buffer. Quality and quan-
tity of DNA were assessed with NanoDrop 1000 (Thermo 
Scientific, Waltham, Massachusetts, USA). DNA samples 
were stored at −20°C until further analyses.
dnA extraction from ileum biopsy
DNA extraction from ileal biopsies was performed using 
GenElute Mammalian Genomic DNA Miniprep Kit 
(Sigma-Aldrich, St.Louis, Missouri, USA) according to 
the manufacturer's instruction. Briefly, few micrograms 
of ileum tissue were added to a solution composed of a 
mixture of lysis solution T and proteinase K, vortexed and 
incubated at 55°C for 5 hours until the complete diges-
tion of the sample. Samples were then incubated at room 
temperature for 2 min with RNase A to eliminate residual 
RNA. Two hundred microlitres of lysis solution C was 
added and samples were incubated at 70°C for 10 min. 
After the column preparation, as indicated by manufac-
turer manual, the lysate was transferred into a column. 
The elution was performed using 100 µl of elution buffer. 
Columns were incubated 5 min at room temperature and 
centrifuged at 6500 g for a minute. The flow-through was 
collected. Obtained DNA was visualised on a UV Transil-
luminator: Gel Doc 2000 (Bio-Rad, Hercules, California, 
USA) after a 0.8% agarose gel electrophoresis to evaluate 
DNA quality and quantified using the spectrophotometer 
Smart-Spec Plus (Bio-Rad). DNA was stored at −20°C for 
further analysis.
Polymerase chain reaction
SFB gene amplification was performed starting from 
150 ng of genomic DNA, in a final volume of 30 µL. Ampli-
fication was carried out in the presence of 1X buffer 
(10 mM Tris-HCl pH 8.8, 1.5 mM MgCl2, 50 mM KCl, 0.1% 
Triton X-100), 33 µM dNTPs, 0.5 µM forward and reverse 
primers (IDT Integrated DNA Technologies, Coralville, 
Iowa, USA), 2U of DyNAzyme II DNA Polymerase (Finn-
zymes, Espoo, Finland) and ultrapure water. Primers 
features are summarised in table 1. Each reaction was 
subjected to an initial denaturation step of 3 min at 96°C. 
The 40 PCR cycles used were as follows: denaturation, 15 s 
at 95°C; annealing, 30 s at 58°C; elongation, 20 s at 72°C. 
The amplification was performed using Gene Amp PCR 
System 9700 thermal cycler (Applied Biosystems, Foster 
City, California, USA). PCR products were analysed by 
2.5% agarose-gel electrophoresis, using ChemiDoc MP 
System (Bio-Rad), image acquisition and analysis was 
performed using Image Lab Software V.4.0 (Bio-Rad). 
The molecular weight marker used was GeneRuler 50 bp 
DNA Ladder (Thermo Scientific) designed to sizing a 
large wide range of double-stranded DNA.
sequencing reaction of Pcr amplicons
Micro-CLEAN (Microzone, Haywards Heath, West 
Sussex, UK) reagent was used to purify PCR products 
from unincorporated primers, according to the manufac-
turer’s instructions. After these purifications, PCR prod-
ucts were sequenced by using the ABI PRISM BigDye 
Terminator Cycle Sequencing Ready Reaction Kit, V.1.0 
(Applied Biosystems-Life Technologies, Carlsbad, Cali-
fornia, USA). Sequencing reactions were performed 
employing both forward and reverse PCR primers, in 
a reaction containing 15 ng of PCR template, 3.2 pmol 
of each sequencing primer, 8 µL of Terminator Ready 
Reaction Mix, in a final volume of 20 µL. The sequencing 
reaction consists of 45 amplification cycles (denatur-
ation: 96°C for 10 s, annealing: 58°C for 5 s, elongation: 
58°C for 3 min; for each cycle). Unincorporated dideoxy-
ribonucleotides were removed from amplicons by using 
a 96-well MultiScreen plate (Merck Millipore, Merck 
KGaA, Darmstadt, Germany) containing Sephadex G-50 
(GE Healthcare, Little Chalfont, Buckinghamshire, 
UK). Electrophoretic separation of sequencing reactions 
was performed by BMR Genomics (BMR Genomics, 
Padua, Italy), and the generated data were analysed by 
the Sequence Scanner software V1.0 (Applied Biosyste-
ms-Life Technologies).
Quantitative real-time Pcr
SFB DNA quantification was performed using real-time 
qPCR, and interleukin 8 (IL-8) gene was used as internal 
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Figure 1 Representative results showing PCR amplification 
of DNA from stools using PCR primers amplifying (A) SFB 
sequences and expected to generate an SFB 139 bp specific 
product or (B) universal PCR primers amplifying bacterial 
16S sequences without species specificity. The generated 
products were analysed by electrophoresis in 2.5% 
agarose. Expected PCR products are arrowed. Sequences 
of the employed PCR primers are reported in table 1. M, 
molecular  wt markers; SFB, segmented filamentous   
bacteria.
reference in order to verify that the same amount of 
DNA was load in each sample. Thirty nanograms of 
total DNA, 150 ng of each primer (IDT, Integrated DNA 
Technologies or Sigma-Aldrich) (table 1) and 1X iTaq 
Universal SYBR Green Supermix (Bio-Rad) were used 
for each reaction, reaching the final volume of 20 µL/
well. The following amplification conditions were used: 
96°C for 3 min, 50 cycles at 95°C for 10 s, 60°C for 30 s 
and 72°C for 25 s, using CFX96 Touch Real-Time PCR 
Detection System (Bio-Rad). A melting curve analysis was 
performed in order to validate primer pairs and amplifi-
cation conditions. Melting curves have been performed 
and the results obtained demonstrated in all the reac-
tions analysed absence of primer dimers. Duplicate nega-
tive controls (no template DNA) were also run to assess 
specificity and to rule out contamination. Data were anal-
ysed using CFX96 Software and the relative quantifica-
tion (fold) of SFB DNA was performed using the ∆∆Ct 
method.
results
Identification of putative sFB sequences in samples of 
terminal ileum of patients with ulcerative colitis and control 
subjects
We first tested, using a PCR approach, the primers 
proposed by Jonsson25 and by Suzuki et al,26 27 and found 
that those proposed by Suzuki et al displayed in our 
experimental conditions good efficiency in generating 
PCR products (data not shown). Due to the unavailability 
of SFB cloned DNA to be used as positive control, the 
PCR reactions were performed on total DNA extracted 
from faecal samples from stools of young children at 
their weaning time, a period in which SFB infection and 
colonisation frequently takes place in animal models 
(figure 1). In these experiments, 150 ng of input DNA 
was used and gene amplification was conducted using 
PCR primers amplifying SFB sequences (figure 1A) (for 
the sequences of the primers used in our experiments, 
see table 1) as well as universal PCR primers18 28 ampli-
fying bacterial 16S ribosomal DNA sequences without 
any species specificity (figure 1B). The stool samples 
were all positive to SFB amplification, despite the fact 
that different amounts of 134 bp SFB PCR products 
were obtained. The identity of amplified PCR products 
with SFB was verified by DNA sequencing. Second, the 
experiments were performed on samples isolated from 
terminal ileum. Figure 2 shows SFB-specific amplification 
and bacterial 16S ribosomal DNA amplification, from the 
terminal ileum of patients with ulcerative colitis (n=10) 
(A and C) and of subjects without evidence of intestinal 
disease (n=8) (B and D). In these experiments, 150 ng 
of input DNA was used. A final comment concerning 
this first approach is that putative SFB sequences were 
present both in patients with ulcerative colitis and in 
control subjects and that this PCR amplification gives rise 
to a 139 bp PCR product, as expected (NCBI Reference 
Sequence Database, KC135882.1). To further sustain this 
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Figure 2 PCR amplification of genomic DNA from patients with ulcerative colitis (RCU) (A and C), and healthy subjects (B 
and D) using PCR primers amplifying SFB sequences and expected to generate an SFB 139 bp specific product (A and B) or 
universal PCR primers amplifying bacterial 16S sequences without species specificity and originating a 145 bp product (C and 
D). For nucleotide sequences, see table 1.  SFB,  segmented  filamentous  bacteria. 
conclusion, the 139 bp PCR products were sequenced. 
In online supplementary figure S1,  an electrophero-
gram section is depicted obtained sequencing the PCR 
product amplified from a colorectal ulcerative colitis 
(RCU) biopsy sample, to be considered as a representa-
tive example of the results obtained. When the sequences 
obtained from the PCR-positive stool samples and from 
three randomly selected bioptic samples (two RCU 
patients and one donor) were compared with known 
sequences retrieved in the NCBI Reference Sequence 
Database, the highest homology, with up to 94% iden-
tity, was found with entries related to Candidatus arthrom-
itus sp. SFB isolated from mouse (NZ_AGAG01000005.1, 
NZ_CP008713.1, NC_017294.1 and NC_015913.1), rat 
(NC_016012.1), turkey (NZ_LXFF01000001.1) and 
human (KC 135882.1) (online supplementary table S1). 
Sequence variability with the only human SFB sequence 
available is expected in different isolates as well as the 
finding that the SFB sequence is conserved when the 
isolate is analysed in different species. Altogether, these 
data support the concept that the employed PCR primers 
allow amplification of putative SFB sequences.
real-time qPcr analysis
Figure 3A (left side of the panel) shows the real-time 
qPCR analysis performed using the primers proposed 
by Suzuki et al.26 27 As internal control, we used primers 
amplifying a human genomic region (the IL-8 gene) 
(figure 3A, right side of the panel).29 This was done in 
order to be confident about the input amount of DNA 
used in the qPCR mixture. In order to verify the coher-
ence of these data with those shown in figure 2 and 
based on semiquantitative PCR, samples generating no 
PCR amplification in figure 2 (n=4) were compared with 
samples generating the highest levels of PCR products 
(n=3). As clearly shown, a statistically significant differ-
ence in SFB/IL-8 fold change was observed (figure 3B). 
Melting curves obtained with real-time qPCR analysis 
demonstrated the absence of primer dimers in all the 
reactions analysed (figure 4A). The data of qPCR confirm 
the presence of putative SFB sequences in samples from 
healthy subjects (figure 4B, samples a–h). When samples 
from RCU (figure 4B, samples 1–10) and healthy 
subjects (figure 4B, samples a–h) were compared, no 
statistically significant difference was found (figure 4C). 
However, the results obtained using the samples from the 
terminal ileum of patients with ulcerative colitis suggest 
a possible association between the bacterial load of SFB 
and the activity of the disease (see the complete set of 
data shown in table 2). In particular, the samples from 
active patients (#2, #3, #4, #8 and #9) showed SFB qPCR 
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Figure 3 Real-time quantitative PCR analysis. Results obtained using genomic DNA samples of biopsies from patients 
with ulcerative colitis (RCU) and healthy subjects are shown. (A) The employed PCR primers (see table 1 for nucleotide 
sequences) were reported to amplify SFB (on the left) and IL-8 (in the right). (B) In order to verify the coherence of these 
data with those shown in figure 2 and based on semiquantitative PCR, samples generating no PCR amplification in figure 2 
(n=4) were compared with samples generating the highest levels of PCR products (n=3). IL-8, interleukin 8; SFB, segmented 
filamentous  bacteria. 
reaction products higher, although not reaching statisti-
cally significant values (P value=0.2997), when compared 
with samples obtained from patients in remission (#1, 
#5, #6, #7 and #10) (figure 4D). This tendency of active 
disease samples to show higher SFB load suggests that the 
SFB load might be somehow related to the clinical stage 
of the ulcerative colitis disease.
dIscussIon
Most of our knowledge about SFB prevalence and body 
habitat derives from studies in animal systems. The 
study on SFB in humans is hampered by lack of knowl-
edge about bacterial variations among different host 
species and, therefore, also by the lack of suitable specific 
reagents. An additional difficulty is represented by the 
clinical material to be analysed, that is, morpholog-
ical studies require bioptic samples. Therefore, molec-
ular analyses performed on faecal samples represent 
a valuable option, as already reported in the scientific 
literature.18 Yin et al18 analysed by PCR stool specimens 
from healthy human individuals of different ages and 
showed that SFB colonisation is age dependent, occur-
ring within the first 2 years of age. Our analysis of a very 
limited number of faecal samples from children at the 
time of their weaning showed highly frequent positivity, 
confirming the observation by Yin et al about colonisation 
at a very young age, and further delimitates it to the time 
of weaning (or before).
This is the first study in which PCR methods are used 
to identify SFB in biopsies from the terminal ileum of 
patients with ulcerative colitis and control subjects. Our 
results confirm that quantitative and qualitative PCR may 
represent a useful tool for the detection of SFB pres-
ence and analysis of the bacterial load. From our study, 
it is possible to conclude that putative SFB sequences are 
present in both patients with ulcerative colitis and control 
subjects. Therefore, it appears that SFB cannot be consid-
ered as being uniquely associated with the disease. On 
the other hand, a second very important finding of our 
study is that among the patients with ulcerative colitis a 
close tendency does exist between bacterial presence and 
density and activity of the disease. A possible hypothesis, 
also based on the physiological role played by SFB on 
the maturation and the differentiation of the immune 
system, is that SFB is normally present in healthy subjects. 
In patients with ulcerative colitis, SFB presence and 
density do not appear directly related to the pathogenesis 
of the disease which could be linked to other microbio-
logical and genetic factors; however, the disease may not 
be able to express themselves in the acute phase in the 
absence of SFB for the peculiar relationship of this bacte-
rium with some components of the immune response, 
particularly in respect to Th-17 lineage.
Notably, SFB has been recognised as the only member 
of the gut microflora exhibiting the ability of inducing 
specific immune responses: in fact, SFB can be consid-
ered as the most potent microbial stimulus inducing 
intestinal IgA-producing cells,9 30 since it was found to 
induce the development of IgA plasma cells in the gut 
lamina propria and natural IgA occurring gut secre-
tions. On the other hand, an aberrant and persistent SFB 
expansion throughout the small intestine has also been 
shown in IgA-deficient mice.26 In addition, SFB selectively 
induces the expression of the major histocompatibility 
complex class II molecules on the intestinal epithelial 
cells.9 More importantly, T-cell-mediated immunological 
responses are specifically induced by SFB. In this respect, 
natural killer  (NK) cells and CD8+ T cells colonisation 
of mice by SFB induces a significant increase in cytotoxic 
activity.19 Given the influence of SFB on many players of 
 7Finotti A, et al. BMJ Open Gastro 2017;4:e000172. doi:10.1136/bmjgast-2017-000172
Open Access
Figure 4 Analysis of SFB-specific sequences in genomic DNA samples of biopsies from patients with ulcerative colitis 
(RCU) and healthy subjects: quantitative determination. (A) Melting curves obtained in real-time qPCR with SFB-specific 
amplification. (B) Fold change with respect to healthy subjects. (B) Fold change of SFB/IL-8-specific amplification of healthy 
tissue with respect to RCU. (C) Fold change SFB/IL-8 of active with respect to remission RCU samples. IL-8, interleukin 8; SFB, 
segmented  filamentous  bacteria. 
the immune response, it seems quite possible that this 
bacterium can interfere with the expression and the 
activity of ulcerative colitis. It should also be underlined 
that SFB does not cause an apparent inflammatory reac-
tion in the lamina propria of colonised areas16 31 and is 
therefore not considered a pathogenic bacteria.
These SFB biological effects might open new perspec-
tives about possible pharmacological development of 
new therapeutic approaches, also considering that both 
antibiotics and probiotics have been found active against 
SFB in mice. In this respect, penicillin displayed the 
potential of eliminating SFB from the mouse terminal 
ileum as a first-step response, but some weeks after the 
halting of the antibiotic treatment a recolonisation of the 
ileum observed was reproducible.32 In addition, the high 
increase of SFB load in ileum samples of immunosup-
pressed mice was brought again into normal values when 
animals received the probiotic Lactobacillus plantarum.33 
Chemotherapic cycles with effective antibiotics may 
induce rapid remission of active disease and the remis-
sion could be maintained through successive appropri-
ately seriated antibiotic cycles over time. Although both 
antibiotic and probiotic treatments have shown some 
beneficial effects in the treatment of ulcerative colitis, 
their clinical use is limited so far. In relation to antibiotic 
therapy, fewer data are available in ulcerative colitis than 
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Table 2 SFB loading in the clinical samples studied
Sample name/number Age Sex Activity CT SFB CT IL-8 Fold SFB/IL-8
Healthy subjects
  a 70 Male n.a. 28.55 24.32 1
  b 67 Male n.a. 26.36 24.62 5.62
  c 50 Female n.a. 29.82 24.14 0.37
  d 68 Female n.a. 29.58 24.11 0.42
  e 72 Male n.a. 23.98 24.06 19.84
  f 65 Female n.a. 26.31 23.72 3.11
  g 36 Female n.a. 27.42 23.89 1.62
  h 55 Male n.a. 32.15 24.46 0.09
RCU subjects 
  1 52 Male Remission 31.58 24.58 0.15
  2 48 Male Active 29.77 24.41 0.4
  8 70 Male Active 25.61 24.08 6.48
  9 28 Female Active 28.1 24.75 1.83
  3 35 Male Active 28.65 24.23 0.88
  4 42 Female Active 27.15 24.34 2.68
  5 35 Female Remission 31.17 24.54 0.19
  6 66 Male Remission 32.98 24.55 0.05
  7 54 Male Remission 27.61 24.99 3.04
  10 40 Female Remission 31.66 24.11 0.1
IL-8, interleukin-8; SFB, segmented  filamentous  bacteria.
in Crohn’s disease and the majority of them consists of 
limited small trials of ciprofloxacin, metronidazole and 
rifaximin based.34 As the outcome of these trials was not 
associated with a benefit for the treatment of active ulcer-
ative colitis, two meta-analyses conducted by Wang et al35 
and Khan et al36 concluded that antibiotic therapy leads 
to a moderate improvement of the clinical symptoms. 
While these data are clearly insufficient, our preliminary 
findings concerning SFB in patients with ulcerative colitis 
may influence the future research in this field. On the 
other hand, outcomes of an important meta-analysis by 
using probiotics in patients with ulcerative colitis37 seem 
to confirm that the use of lactobacilli speculatively able 
to compete for the attachment to the specialised epithe-
lium in the terminal ileum is as effective as with standard 
mesalazine in maintaining remission.
Further investigations have to be carried out both 
to confirm these preliminary findings in a more large 
sample of patients and controls and to evaluate the anti-
biotic effectiveness in reducing the presence or the load 
of SFB by qualitative and quantitative PCR. The corollary 
successive research would be to identify more successful 
antibiotic and/or probiotic treatments to eradicate the 
presence and/or reduce the density of SFB, also evalu-
ating these treatments in relation to the acute phase and 
maintaining remission of ulcerative colitis.
Acknowledgements We would like to thank Dr Eleonora Brognara and Dr Cristina 
Zuccato for technical assistance and support. 
contributors AF, DDL, RG, MC: study concept and design; GM, VM, VG, MC: 
collection of biological material; AF, JG, IL, LCC, VG: performing the experiments 
on biological material; AF, JG, IL, DDL, RG, MC: analysis and interpretation of data; 
AF, JG, GM, DDL, RG, MC: writing and editing of the manuscript; GM, DDL, RG, MC: 
critical revision of the manuscript and important intellectual content. All authors 
approved the final draft of this manuscript for submission.
Funding This research was supported by grants from Consorzio Interuniversitario 
di Biotecnonologie (CIB) 2016, and by Fondo per le Agevolazioni alla Ricerca (FAR 
2016) of Italian Ministry of Education, Universities and Research.
competing interests None declared.
Ethics approval The protocol was approved by the local Ethics Committee of 
Azienda Ospedaliera Universitaria di Ferrara (Protocol n.86–2013, 20 June 2013). 
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement ll relevant data are within the paper and its supporting 
materials 
Open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
rEFErEncEs
 1. Leidy J. On the existence of entophyta in healthy animals, as a 
natural condition. Proc Acad Natl Sci Phila 1849;4:225–33.
 2. Ivanov II, Littman DR. Segmented filamentous bacteria take the 
stage. Mucosal Immunol 2010;3:209–12.
 9Finotti A, et al. BMJ Open Gastro 2017;4:e000172. doi:10.1136/bmjgast-2017-000172
Open Access
 3. Klaasen HL, Koopman JP, Van den Brink ME, et al. Intestinal, 
segmented, filamentous bacteria in a wide range of vertebrate 
species. Lab Anim 1993;27:141–50.
 4. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells 
by segmented filamentous bacteria. Cell 2009;139:485–98.
 5. Gaboriau-Routhiau V, Rakotobe S, Lécuyer E, et al. The key role of 
segmented filamentous bacteria in the coordinated maturation of gut 
helper T cell responses. Immunity 2009;31:677–89.
 6. Lee YK, Menezes JS, Umesaki Y, et al. Proinflammatory T-cell 
responses to gut microbiota promote experimental autoimmune 
encephalomyelitis. Proc Natl Acad Sci U S A  
2011;108 (Suppl 1):4615–22.
 7. Chappert P. Role of SFB in autoimmune arthritis: an example of 
regulation of autoreactive T cell sensitivity in the gut. Gut Microbes 
2014;5:259–64.
 8. Kriegel MA, Sefik E, Hill JA, et al. Naturally transmitted segmented 
filamentous bacteria segregate with diabetes protection in nonobese 
diabetic mice. Proc Natl Acad Sci U S A 2011;108:11548–53.
 9. Umesaki Y, Setoyama H, Matsumoto S, et al. Differential roles of 
segmented filamentous bacteria and clostridia in development of the 
intestinal immune system. Infect Immun 1999;67:3504–11.
 10. Child MW, Kennedy A, Walker AW, et al. Studies on the effect of 
system retention time on bacterial populations colonizing a three-
stage continuous culture model of the human large gut using FISH 
techniques. FEMS Microbiol Ecol 2006;55:299–310.
 11. Caselli M, Tosini D, Gafà R, et al. Segmented filamentous bacteria-
like organisms in histological slides of ileo-cecal valves in patients 
with ulcerative colitis. Am J Gastroenterol 2013;108:860–1.
 12. Ferguson DJ, Birch-Andersen A. Electron microscopy of a 
filamentous, segmented bacterium attached to the small intestine 
of mice from a laboratory animal colony in Denmark. Acta Pathol 
Microbiol Scand B 1979;87:247–52.
 13. Davis CP, Savage DC. Habitat, succession, attachment, and 
morphology of segmented, filamentous microbes indigenous to the 
murine gastrointestinal tract. Infect Immun 1974;10:948–56.
 14. Snel J, Hermsen CC, Smits HJ, et al. Interactions between gut-
associated lymphoid tissue and colonization levels of indigenous, 
segmented, filamentous bacteria in the small intestine of mice. Can J 
Microbiol 1998;44:1177–82.
 15. Garland CD, Lee A, Dickson MR. Segmented filamentous bacteria 
in the rodent small intestine: Their colonization of growing animals 
and possible role in host resistance toSalmonella. Microb Ecol 
1982;8:181–90.
 16. Caselli M, Holton J, Boldrini P, et al. Morphology of segmented 
filamentous bacteria and their patterns of contact with the follicle-
associated epithelium of the mouse terminal ileum. Gut Microbes 
2010;1:367–72.
 17. Ericsson AC, Turner G, Montoya L, et al. Isolation of segmented 
filamentous bacteria from complex gut microbiota. Biotechniques 
2015;59:94–8.
 18. Yin Y, Wang Y, Zhu L, et al. Comparative analysis of the distribution 
of segmented filamentous bacteria in humans, mice and chickens. 
Isme J 2013;7:615–21.
 19. Cebra JJ, Periwal SB, Lee G, et al. Development and maintenance 
of the gut-associated lymphoid tissue (GALT): the roles of enteric 
bacteria and viruses. Dev Immunol 1998;6:13–18.
 20. Schnupf P, Gaboriau-Routhiau V, Cerf-Bensussan N. Host 
interactions with Segmented Filamentous Bacteria: an unusual 
trade-off that drives the post-natal maturation of the gut immune 
system. Semin Immunol 2013;25:342–51.
 21. Prakash T, Oshima K, Morita H, et al. Complete genome sequences 
of rat and mouse segmented filamentous bacteria, a potent inducer 
of th17 cell differentiation. Cell Host Microbe 2011;10:273–84.
 22. Pamp SJ, Harrington ED, Quake SR, et al. Single-cell sequencing 
provides clues about the host interactions of segmented filamentous 
bacteria (SFB). Genome Res 2012;22:1107–19.
 23. Caselli M, Cassol F, Gentili V, et al. Genome sequences of 
segmented filamentous bacteria in animals: implications for human 
research. Gut Microbes 2012;3:401–5.
 24. Urdaci MC, Regnault B, Grimont PA. Identification by in situ 
hybridization of segmented filamentous bacteria in the intestine 
of diarrheic rainbow trout (Oncorhynchus mykiss). Res Microbiol 
2001;152:67–73.
 25. Jonsson H. Segmented filamentous bacteria in human ileostomy 
samples after high-fiber intake. FEMS Microbiol Lett 2013;342:24–9.
 26. Suzuki K, Meek B, Doi Y, et al. Aberrant expansion of segmented 
filamentous bacteria in IgA-deficient gut. Proc Natl Acad Sci U S A 
2004;101:1981–6.
 27. Shukla R, Ghoshal U, Dhole TN, et al. Fecal microbiota in patients 
with irritable bowel syndrome compared with healthy controls using 
real-time polymerase chain reaction: an evidence of dysbiosis. Dig 
Dis Sci 2015;60:2953–62.
 28. Denman SE, McSweeney CS. Development of a real-time PCR 
assay for monitoring anaerobic fungal and cellulolytic bacterial 
populations within the rumen. FEMS Microbiol Ecol 2006;58:572–82.
 29. Finotti A, Borgatti M, Bezzerri V, et al. Effects of decoy molecules 
targeting NF-kappaB transcription factors in Cystic fibrosis IB3-1 
cells: recruitment of NF-kappaB to the IL-8 gene promoter and 
transcription of the IL-8 gene. Artif DNA PNA XNA 2012;3:97–104.
 30. Talham GL, Jiang HQ, Bos NA, et al. Segmented filamentous 
bacteria are potent stimuli of a physiologically normal state 
of the murine gut mucosal immune system. Infect Immun 
1999;67:1992–2000.
 31. Yamauchi K, Isshiki Y, Zhou ZX, et al. Scanning and transmission 
electron microscopic observations of bacteria adhering to ileal 
epithelial cells in growing broiler and white leghorn chickens. Br 
Poult Sci 1990;31:129–37.
 32. Davis CP, Savage DC. Effect of penicillin on the succession, 
attachment, and morphology of segmented, filamentous microbes in 
the murine small bowel. Infect Immun 1976;13:180–8.
 33. Fuentes S, Egert M, Jimenez-Valera M, et al. A strain of Lactobacillus 
plantarum affects segmented filamentous bacteria in the intestine of 
immunosuppressed mice. FEMS Microbiol Ecol 2008;63:65–72.
 34. Nitzan O, Elias M, Peretz A, et al. Role of antibiotics for 
treatment of inflammatory bowel disease. World J Gastroenterol 
2016;22:1078–87.
 35. Wang SL, Wang ZR, Yang CQ. Meta-analysis of broad-spectrum 
antibiotic therapy in patients with active inflammatory bowel disease. 
Exp Ther Med 2012;4:1051–6.
 36. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in 
inflammatory bowel disease: a systematic review and meta-analysis. 
Am J Gastroenterol 2011;106:661–73.
 37. Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission 
and maintaining therapy in ulcerative colitis, Crohn's disease, and 
pouchitis: meta-analysis of randomized controlled trials. Inflamm 
Bowel Dis 2014;20:21–35.
